SaaS Metrics
Patient Safety, Market Adoption
Clinical Effectiveness
AI Synthesis & Market Narrative
Continuous IV monitoring technology (ivWatch) is gaining market access through major healthcare systems like the UK NHS Supply Chain, driven by its demonstrated clinical effectiveness in reducing patient harm. This reflects a broader market demand for science-backed solutions that enhance patient safety and outcomes.
Correlated Linguistic Patterns
["ivWatch: Innovative Technology Now Available Through UK NHS Supply Chain"
"continuous IV monitoring to reduce avoidable extravasation harm"
"greater demand for science-backed solutions"
"Safety and operational feasibility of single versus cocktail rabies monoclonal antibodies"]
Driving Media Context
Organyc® Refreshes Brand Identity to Help Women Shop Smarter, Reinforcing Its Commitment to a Lifetime of Protection for Sensitive Skin
The new website, packaging and logo reflect how women shop today, with greater demand for science-backed solutions, clear education and products tailored to ...
WHO Expects Cancer Cases To SOAR GLOBALLY
The World Health Organization (WHO) expects cancer cases to soar all over the globe. The WHO made this announcement in a report released on Wednesday, in whi...
Safety and operational feasibility of single versus cocktail rabies monoclonal antibodies for post-exposure prophylaxis in a resource-limited setting
Author summary Rabies is a deadly but preventable disease that continues to cause thousands of deaths each year, mostly in resource-limited settings. After a...
KARL STORZ Expands Its Robotics Ecosystem Through Strategic Partnerships in the US
TUTTLINGEN, Germany — Through new strategic partnerships across the robotics ecosystem in the United States, the family-owned MedTech company KARL STORZ is b...
ivWatch: Innovative Technology Now Available Through UK NHS Supply Chain
Disruptive innovation provides NHS Trusts faster access to continuous IV monitoring to reduce avoidable extravasation harm NEWPORT NEWS, Va. and LONDON, July...
ivWatch: Innovative Technology Now Available Through UK NHS Supply Chain
Disruptive innovation provides NHS Trusts faster access to continuous IV monitoring to reduce avoidable extravasation harm NEWPORT NEWS, Va. and LONDON, July...
Personalised approach to hypertension treatment: protocol for the HYPERMARKER randomised controlled trial
Chapman, M., Knikman, J. E., Mobley, A., Lagerwaard, B., Martinez-Garcia, F., Zeitouny, S. ORCID logo , Engler, D., Schnabel, R. B., Spiering, W., Bos, I. D....
'Heartbreaking' - Campaigners criticise rare disease drug delays
People living with Friedreich's Ataxia have criticised the latest delay in the decision on whether to reimburse Skyclarys
'Heartbreaking' - Campaigners criticise rare disease drug delays
People living with Friedreich's Ataxia have criticised the latest delay in the decision on whether to reimburse Skyclarys
DNV Healthcare renews ISQua accreditation for global hospital standards
Independent review confirms DNV's hospital standards continue to meet international healthcare accreditation principles. HOUSTON, July 15, 2026 /PRNewswire/ ...